Ferumoxytol for Treating Iron Deficiency Anemia in CKD

Overview

Journal J Am Soc Nephrol

Specialty Nephrology

Date 2008 Jun 6

PMID 18525001

Citations 104

Authors

Bruce S Spinowitz

Annamaria T Kausz

Jovanna Baptista

Sylvia D Noble

Renuka Sothinathan

Marializa V Bernardo

Louis Brenner

Brian J G Pereira

Affiliations

Soon will be listed here.

Abstract

Iron deficiency is an important cause of anemia in patients with chronic kidney disease (CKD), but intravenous iron is infrequently used among patients who are not on dialysis. Ferumoxytol is a novel intravenous iron product that can be administered as a rapid injection. This Phase III trial randomly assigned 304 patients with CKD in a 3:1 ratio to two 510-mg doses of intravenous ferumoxytol within 5 +/- 3 d or 200 mg of elemental oral iron daily for 21 d. The increase in hemoglobin at day 35, the primary efficacy end point, was 0.82 +/- 1.24 g/dl with ferumoxytol and 0.16 +/- 1.02 g/dl with oral iron (P < 0.0001). Among patients who were not receiving erythropoiesis-stimulating agents, hemoglobin increased 0.62 +/- 1.02 g/dl with ferumoxytol and 0.13 +/- 0.93 g/dl with oral iron. Among patients who were receiving erythropoiesis-stimulating agents, hemoglobin increased 1.16 +/- 1.49 g/dl with ferumoxytol and 0.19 +/- 1.14 g/dl with oral iron. Treatment-related adverse events occurred in 10.6% of patients who were treated with ferumoxytol and 24.0% of those who were treated with oral iron; none was serious. In summary, a regimen of two doses of 510 mg of intravenous ferumoxytol administered rapidly within 5 +/- 3 d was well tolerated and had the intended therapeutic effect. This regimen may offer a new, efficient option to treat iron deficiency anemia in patients with CKD.

Citing Articles

Ranking Magnetic Colloid Performance for Magnetic Particle Imaging and Magnetic Particle Hyperthermia.

Carlton H, Salimi M, Arepally N, Bentolila G, Sharma A, Bibic A Adv Funct Mater. 2025; 35(2):2412321.

PMID: 39882193 PMC: 11774450. DOI: 10.1002/adfm.202412321.

3D electron microscopy for analyzing nanoparticles in the tumor endothelium.

Mladjenovic S, Chandok I, Darbandi A, Nguyen L, Stordy B, Zhen M Proc Natl Acad Sci U S A. 2024; 121(51):e2406331121.

PMID: 39665759 PMC: 11665908. DOI: 10.1073/pnas.2406331121.

Cerebral Aneurysm: Filling the Gap Between Pathophysiology and Nanocarriers.

Toader C, Radoi M, Covlea C, Covache-Busuioc R, Ilie M, Glavan L Int J Mol Sci. 2024; 25(22).

PMID: 39595942 PMC: 11593836. DOI: 10.3390/ijms252211874.

Oral Liposomal Iron Versus Injectable Iron Sucrose for Anemia Treatment in Non-dialysis Chronic Kidney Disease Patients: A Non-inferiority Study.

Bengelloun Zahr S, Allata Y, El Mansoury M, Chouhani B, Kabbali N, El Bardai G Cureus. 2024; 16(9):e70114.

PMID: 39449947 PMC: 11501097. DOI: 10.7759/cureus.70114.

Ferumoxytol-enhanced MR venography for mapping lower-extremity venous networks and evaluating varicose veins in patients with diabetes.

Liu Y, Cao B, Wang X, Zhong J, Li Z, Peng R Eur Radiol. 2024; 34(11):7197-7207.

PMID: 38713277 DOI: 10.1007/s00330-024-10772-x.

References

Fishbane S . Safety in iron management. Am J Kidney Dis. 2003; 41(5 Suppl):18-26. DOI: 10.1016/s0272-6386(03)00373-1. View

Gotloib L, Silverberg D, Fudin R, Shostak A . Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006; 19(2):161-7. View

Singh A, Szczech L, Tang K, Barnhart H, Sapp S, Wolfson M . Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355(20):2085-98. DOI: 10.1056/NEJMoa065485. View

Astor B, Muntner P, Levin A, Eustace J, Coresh J . Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2002; 162(12):1401-8. DOI: 10.1001/archinte.162.12.1401. View

Fishbane S, Maesaka J . Iron management in end-stage renal disease. Am J Kidney Dis. 1997; 29(3):319-33. DOI: 10.1016/s0272-6386(97)90192-x. View

. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ. 1990; 300(6724):573-8. PMC: 1662387. DOI: 10.1136/bmj.300.6724.573. View

Kazmi W, Kausz A, Khan S, Abichandani R, Ruthazer R, Obrador G . Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis. 2001; 38(4):803-12. DOI: 10.1053/ajkd.2001.27699. View

Van Wyck D, Roppolo M, Martinez C, Mazey R, McMurray S . A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005; 68(6):2846-56. DOI: 10.1111/j.1523-1755.2005.00758.x. View

Eschbach J . The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989; 35(1):134-48. DOI: 10.1038/ki.1989.18. View

10.

Obrador G, Ruthazer R, Arora P, Kausz A, Pereira B . Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol. 1999; 10(8):1793-800. DOI: 10.1681/ASN.V1081793. View

11.

Mafra D, Cuppari L, Cozzolino S . Iron and zinc status of patients with chronic renal failure who are not on dialysis. J Ren Nutr. 2002; 12(1):38-41. DOI: 10.1053/jren.2002.29597. View

12.

Chertow G, Mason P, Vaage-Nilsen O, Ahlmen J . Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2005; 21(2):378-82. DOI: 10.1093/ndt/gfi253. View

13.

Macdougall I . Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999; 69:S61-6. DOI: 10.1046/j.1523-1755.1999.055suppl.69061.x. View

14.

Chandler G, Harchowal J, Macdougall I . Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis. 2001; 38(5):988-91. DOI: 10.1053/ajkd.2001.28587. View

15.

Fletes R, Lazarus J, Gage J, Chertow G . Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis. 2001; 37(4):743-9. DOI: 10.1016/s0272-6386(01)80123-2. View

16.

Bailie G, Clark J, Lane C, Lane P . Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant. 2005; 20(7):1443-9. DOI: 10.1093/ndt/gfh820. View

17.

Macdougall I, Roche A . Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. Am J Kidney Dis. 2005; 46(2):283-9. DOI: 10.1053/j.ajkd.2005.04.032. View

18.

Charytan C, Qunibi W, Bailie G . Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005; 100(3):c55-62. DOI: 10.1159/000085049. View

19.

Akmal M, Sawelson S, Karubian F, Gadallah M . The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy. Clin Nephrol. 1994; 42(3):198-202. View

20.

Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt K . Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19 Suppl 2:ii1-47. DOI: 10.1093/ndt/gfh1032. View